Search the Newsreel

Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump

Fat Prophets Global Contrarian Fund Pre-Tax NTA Rises 8.072% to $1.8917 as at 12 August 2026

ConocoPhillips’ Coyote 3SX Strikes First Oil

ConocoPhillips Alaska announced that its Coyote 3SX development in the Kuparuk River Unit achieved first oil ahead of schedule and under budget on August 7, 2026. The $800 million project, which began construction in early 2026, is expected to reach a peak oil rate …

What's Going On With Helix BioPharma Corp. Stock Thursday?

ConocoPhillips’ Middle East Bets in Iraq, Syria Are a New Cash Driver

ConocoPhillips is expanding its presence in the Middle East, specifically in Iraq and Syria, which is anticipated to generate new cash flow. The company recently agreed to acquire a 42% interest in BP Energy Co. of Kirkuk Ltd., supporting the redevelopment of four oil …

ConocoPhillips Alaska brings its Coyote 3SX project online early

ConocoPhillips Alaska announced that its Coyote 3SX project achieved first oil on August 7, 2026, ahead of schedule and under budget. This expansion project, part of the Kuparuk River unit, involved 19 development wells and 20 miles of new pipeline, and is expected to …

Dawson Geophysical Company (DWSN) Releases Q2 2026 Earnings: Revenue Up 81.8% but Losses Persist

Dawson Geophysical Company (DWSN) reported a significant 81.8% increase in Q2 2026 revenue, reaching $17.9 million, with gross profit more than doubling to $2.6 million. Despite this strong top-line growth and positive operating cash flow of $6.5 million, the company still posted an operating …

Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary

Karyopharm Therapeutics Inc. reported its Q2 2026 financial results, showing a decrease in revenue to $33.4M and an increased net loss of $67M, with a diluted loss per share of $(2.32). Despite a YoY revenue decline for the quarter, six-month net product revenue increased …

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …

Dawson Geophysical reports Q2 revenue up 82%, net loss narrows, and positive EBITDA for 4th quarter in a row.

Dawson Geophysical Company reported a significant 82% increase in Q2 2026 revenues to $17.9 million. Despite a net loss of $3.4 million due to strategic transaction costs, the company achieved positive Adjusted EBITDA for the fourth consecutive quarter. This indicates improving operational efficiency and …

Dawson Geophysical (NASDAQ:DWSN) Announces Earnings Results

Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock

Verve Capital Limited has reported a 6.3% beneficial ownership stake in Vor Biopharma Inc. (VOR) common stock as of June 30, 2026. This ownership includes 3,410,892 shares, with Verve Capital holding sole voting and dispositive power. The filing, an amended SCHEDULE 13G/A, was signed …

Dawson Geophysical: Q2 Earnings Snapshot

Aspire Biopharma (NASDAQ: ASBP) slashes H1 2026 loss and rebuilds equity

Aspire Biopharma (NASDAQ: ASBP) reported significantly reduced net losses in the first half of 2026, dropping to $4.49 million from $17.92 million a year prior, largely due to lower stock-based compensation and financing costs. The company also substantially improved its balance sheet, moving from …

Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt

ConocoPhillips stock underperforms Thursday when compared to competitors

ConocoPhillips (COP) stock declined by 2.18% on Thursday, closing at $124.52. This underperformance occurred despite a positive trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. The stock's fall also broke a five-day …

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Karyopharm Therapeutics has cash to last only into next month

Newton-based biotech Karyopharm Therapeutics is facing a severe cash crisis, with its funding expected to run out within weeks. The company also has a significant debt payment due in September, putting it at risk of default without new financing. Richard Paulson is the CEO …

VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18

Wedbush has increased its target price for VOR Biopharma Inc. from $18 to $27. This adjustment reflects a more optimistic outlook on the company's financial prospects by the analyst firm. The article is a brief news update published on Webull.

Why Helix BioPharma Corp. stock is rising today

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock, representing 14.0% of the class. These shares are held in client accounts, known as Managed Portfolios, where Janus Henderson's asset managers …

Resilient ConocoPhillips stock holds gains as new CEO and Alaska Coyote project reshape outlook

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

ArriVent BioPharma reported its second-quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects topline data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026, and its cash and investments of $373.1 million …

Form 8K ABVC Biopharma Inc For: 12 August By Investing.com

This article reports on ABVC Biopharma Inc.'s Form 8K filing for August 12. The filing is a standard requirement for publicly traded companies to announce significant events that shareholders should know. The article provides the title of the filing and mentions the company's stock …

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple

ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings

ArriVent BioPharma (NASDAQ:AVBP) experienced a 4.7% drop in share price after reporting weaker-than-expected quarterly earnings, missing analyst estimates by $0.06 with a $1.05-per-share loss. Despite the share price decline and significantly lower trading volume, analyst sentiment remains largely positive, holding a "Moderate Buy" consensus …

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

Zenas BioPharma (NASDAQ:ZBIO) experienced a 6.6% stock price drop after reporting disappointing quarterly earnings, with an EPS of $(1.77) against an estimated $(1.12) and revenue of $1 million against a $15 million forecast. Despite the earnings miss, analysts generally maintain a "Moderate Buy" rating …

ConocoPhillips taps O’Brien for CEO role, elevates Haynes-Welsh to CFO

ConocoPhillips has announced a leadership succession plan, appointing Andy O’Brien as the new President and CEO, effective September 1, 2026. O’Brien, currently CFO, will succeed Ryan Lance, who is retiring. Konnie Haynes-Welsh will be elevated to Senior Vice President and CFO.

Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush

Wedbush has reiterated an "outperform" rating for Sutro Biopharma (NASDAQ:STRO) with a $60 price target, suggesting a significant upside. This comes despite the company missing its Q2 earnings and revenue estimates. Several other analysts also hold "Buy" or "Outperform" ratings for the stock, with …

Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results

Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KPTI) 2026-08-13

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Radiopharm Theranostics (RADX) seeks shareholder approval for placements, SPP and new warrants

Radiopharm Theranostics (RADX) is seeking shareholder approval for a multi-component capital raise, including placements, a share purchase plan (SPP), and various options and warrants, at a virtual extraordinary general meeting on September 11, 2026. The company is asking shareholders to ratify previously issued shares …

Following Q2 Earnings And CEO Change, Is ConocoPhillips (COP) Still Trading At A Discount?

ConocoPhillips (COP) reported stronger Q2 2026 results and announced a new CEO, Andy O’Brien, leading to significant recent share price gains. Despite these positive developments and strong market momentum, Simply Wall St's analysis suggests ConocoPhillips is still undervalued, with a fair value of $143.72 …

Karyopharm Therapeutics: Q2 Earnings Snapshot

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

HC Wainwright has reduced its FY2030 EPS forecast for Vor Biopharma to $3.89 from $4.27, though it maintained a "Buy" rating and a $31 price target. The company recently reported quarterly EPS of -$0.80, missing the consensus estimate. Despite the lowered forecast, the overall …